GLP-1s and pregnancy planning: questions to ask before starting or stopping

Bring pregnancy plans up before the first prescription

Pregnancy planning is not a small side note in GLP-1 care. It can affect whether weight-loss medication is appropriate, how contraception is discussed, whether another condition such as diabetes needs a separate plan, and who should coordinate care. Tell the clinician if you are pregnant, trying to become pregnant, could become pregnant, breastfeeding, recently postpartum, or using contraception that could be affected by medication changes.

Weight-loss medication is treated differently in pregnancy

NIDDK says people who are pregnant or planning to become pregnant should not take weight-loss medications because they may harm the fetus, and ACOG's patient guidance says weight-loss medications should not be taken if someone is trying to get pregnant or is already pregnant. FDA-approved product labels also include pregnancy-specific warnings and instructions. Use those sources as a reason to ask a clinician early, not as a self-directed stop-or-start plan.

• Ask whether the medication is being discussed for weight management, diabetes, cardiovascular risk, sleep apnea, MASH, or another indication.
• Ask how pregnancy plans change the medication discussion and whether another clinician should be involved.
• Ask what to do if pregnancy is suspected or confirmed while using medication.
• Ask how nutrition, blood sugar, blood pressure, mental health, and weight history should be monitored if medication is stopped or deferred.

Check the exact medication label

The details are medication-specific. Wegovy prescribing information says it may cause fetal harm and, for weight reduction or cardiovascular risk reduction, should be discontinued when pregnancy is recognized; the label also tells females of reproductive potential to discontinue Wegovy at least 2 months before a planned pregnancy because of the drug's long half-life. Zepbound prescribing information says weight loss offers no benefit to a pregnant patient and may cause fetal harm, and it advises discontinuing Zepbound when pregnancy is recognized. Your clinician should translate the label into your health situation.

• Which active ingredient and product are we discussing: semaglutide, tirzepatide, another GLP-1, or a compounded product?
• What does the current prescribing information say about pregnancy, lactation, and reproductive potential?
• Is there a pregnancy exposure registry or reporting path if exposure already happened?
• Who should I contact first: prescriber, OB-GYN, maternal-fetal medicine, endocrinology, pharmacist, or primary care?

Ask about contraception, especially with tirzepatide

Zepbound labeling says tirzepatide may reduce the efficacy of oral hormonal contraceptives because of delayed gastric emptying, with the largest delay after the first dose. The label advises patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation. That is a clinician conversation, especially if pregnancy prevention is important or if side effects affect medication absorption.

• Does this medication affect my contraception method or timing?
• Should I involve my OB-GYN or primary care clinician before starting or increasing medication?
• What should I do if vomiting, diarrhea, missed pills, or refill delays occur?
• How should contraception questions be documented in my care plan?

Breastfeeding and postpartum care need their own plan

Pregnancy, breastfeeding, and postpartum weight care are not interchangeable situations. NIDDK says weight-loss medications are not recommended if breastfeeding, while product labels and teratology resources discuss limited human data and medication-specific uncertainty. Ask the clinician to separate pregnancy, lactation, diabetes or metabolic care, nutrition, mental health, and long-term weight-management goals instead of treating restart timing as a simple calendar question.

Make care coordination explicit

If more than one clinician is involved, ask who owns the plan before medication decisions become fragmented. A safe plan should say who updates the medication list, who handles pregnancy or breastfeeding questions, who reviews diabetes or blood-pressure medicines, who receives lab results, and what written instructions you should follow if pregnancy is possible or confirmed.